Use and role of monoclonal antibodies and other biologics in preventive cardiology

Swiss Medical Weekly

Volumn 145, Issue , 2015, Pages

  Gencer, Baris ^a   Laaksonen, Reijo ^b   Buhayer, Aliki ^c   Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c Prism Scientific SarL   (Switzerland)

Author keywords

Biologics; Cardiovascular prevention; Familial hypercholesterolaemia; Inflammation; Interleukin 1 inhibitors; Lipids; Monoclonal antibodies; PCSK9 inhibitors

Indexed keywords

ALIROCUMAB; BOCOCIZUMAB; C REACTIVE PROTEIN; CANAKINUMAB; DARAPLADIB; EVOLOCUMAB; EZETIMIBE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSUVASTATIN; SUBTILISIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADAPTIVE IMMUNITY; ANTIBODY SPECIFICITY; ATHEROSCLEROSIS; BIOLOGICAL THERAPY; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FAMILIAL HYPERCHOLESTEROLAEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; OUTCOME ASSESSMENT; PREVENTIVE CARDIOLOGY; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SECONDARY PREVENTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HYPERLIPOPROTEINEMIA TYPE II; MOUSE; PROCEDURES;

ACUTE CORONARY SYNDROME; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE; ATHEROSCLEROSIS; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MICE; PROPROTEIN CONVERTASES; SECONDARY PREVENTION; SERINE ENDOPEPTIDASES;

EID: 84960464002     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2015.14179     Document Type: Review

References (47)

1. Morrow T., Felcone L.H. Defining the difference: What Makes Biologics Unique. Biotechnology healthcare Sep 2004;1(4):24-29
2. Foltz I.N., Karow M., Wasserman S.M. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation 2013;127(22):2222-2230
3. Gencer B., Mach F. Sweetless'n low LDL-C targets for PCSK9 treatment. Eur Heart J. 2015.
4. Gencer B., Lambert G., Mach F. PCSK9 inhibitors. Swiss Med Wkly 2015;145:w14094
5. Segovia J., Rodriguez-Lambert J.L., Crespo-Leiro M.G., et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006;81(11):1542-1548
6. Delgado J.F., Vaqueriza D., Sanchez V., et al. Induction treatment with monoclonal antibodies for heart transplantation. Transplant Rev (Orlando). 2011;25(1):21-26
7. Seidah N.G., Awan Z., Chretien M., Mbikay M. PCSK9: a key modulator of cardiovascular health. Circulation research 2014;114(6):1022-1036
8. Cohen J.C., Boerwinkle E., Mosley TH, Jr., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354(12):1264-1272
9. Sullivan D., Olsson A.G., Scott R., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497-2506
10. Giugliano R.P., Desai N.R., Kohli P., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380(9858):2007-2017
11. Koren M.J., Scott R., Kim J.B., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012;380(9858):1995-2006
12. Raal F., Scott R., Somaratne R., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126(20):2408-2417
13. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366(12):1108-1118
14. Stein E.A., Gipe D., Bergeron J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380(9836):29-36
15. Roth E.M., McKenney J.M., Hanotin C., Asset G., Stein E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367(20):1891-1900
16. Cannon C.P., Cariou B., Blom D., et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015;36(19):1186-1194
17. Robinson J.G., Farnier M., Krempf M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1489-1499
18. Sabatine M.S., Giugliano R.P., Wiviott S.D., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1500-1509
19. Navarese E.P., Kolodziejczak M., Schulze V., et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med 2015.
20. Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A.J. The safety and side effects of monoclonal antibodies. Nature reviews. Drug Discov 2010;9(4):325-338
21. Guan M., Zhou Y., Sun J., Chen S. Events Adverse of Monoclonal Antibodies Used for Cancer Therapy. Biomed Research International 2015.
22. Vogel R.A. PCSK9 inhibition : the next statin?J Am Coll Cardiol. 2012;59(25):2354-2355
23. Schwartz G.G., Bessac L., Berdan L.G., et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 2014;168(5):682-689
24. Catapano A.L., Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013;228(1):18-28
25. Ridker P.M. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J 2014;35(9):540-543
26. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013;368(21):2004-2013
27. Rodondi N., Marques-Vidal P., Butler J., et al. Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. Am J Epidemiol 2010;171(5):540-549
28. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108(19):2317-2322
29. Ridker P.M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009;7(Suppl1):332-339
30. Goff DC, Jr., Lloyd-Jones D.M., Bennett G., et al 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73.
31. Khot U.N., Khot M.B., Bajzer C.T., et al. Prevalence of conventional risk factors in patients with coronary heart diseaseJAMA. 2003;290(7):898-904
32. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-2207
33. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354(15):1578-1588
34. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464(7293):1357-1361
35. Larsen C.M., Faulenbach M., Vaag A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356(15):1517-1526
36. Ridker P.M., Howard C.P., Walter V., et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012;126(23):2739-2748
37. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162(4):597-605
38. Everett B.M., Pradhan A.D., Solomon D.H., et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166(2):199-207 e115.
39. Gerards A.H., de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford). 2003;42(10):1189-1196
40. Krishnan E., Lingala V.B., Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004;110(13):1774-1779
41. Singh J.A., Furst D.E., Bharat A., et al 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625-639
42. Micha R., Imamura F., Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108(9):1362-1370
43. Rho Y.H., Oeser A., Chung C.P., Milne G.L., Stein C.M. Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors. Arch Drug Inf 2009;2(2):34-40
44. White H.D., Held C., Stewart R., et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370(18):1702-1711
45. O'Donoghue M.L., Braunwald E., White H.D., et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trialJAMA. 2014;312(10):1006-1015
46. Abbate A., Kontos M.C., Abouzaki N.A., et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies).Am J Cardiol 2015;115(3):288-292
47. Ruperto N., Brunner H.I., Quartier P., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367(25):2396-2406